Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Patients with Psoriasis from the PsoBioTeq Cohort

被引：3

作者：

Bettuzzi, Thomas ^{[1
,2
,3
]}

Bachelez, Herve ^{[4
,5
]}

Beylot-Barry, Marie ^{[6
]}

Arlegui, Hugo ^{[7
]}

Paul, Carle ^{[8
,9
]}

Viguier, Manuelle ^{[10
]}

Mahe, Emmanuel ^{[11
]}

Beneton, Nathalie ^{[12
]}

Jullien, Denis ^{[13
]}

Richard, Marie-Aleth ^{[14
]}

Joly, Pascal ^{[15
]}

Tubach, Florence ^{[7
]}

Dupuy, Alain ^{[16
,17
]}

Sbidian, Emilie ^{[1
,2
,3
,18
]}

Chosidow, Olivier ^{[1
,2
,19
]}

机构：

[1] Paris Est Creteil Univ, Henri Mondor Hosp, AP HP, Creteil Med Sch, Creteil, France

[2] Paris Est Creteil Univ, Henri Mondor Hosp, AP HP, Dermatol Dept, Creteil, France

[3] Paris Est Creteil Univ, EpiDermE, Creteil, France

[4] Paris Diderot Univ, SorbonneParis Cite, Paris, France

[5] St Louis Hosp, AP HP, Inst Imagine, Dermatol Dept,INSERM UMR 1163, Paris, France

[6] Bordeaux Univ, INSERM 01053, St Andre Hosp, Dermatol Dept, Bordeaux, France

[7] Sorbonne Univ, Pitie Salpetriere Hosp, AP HP,Pierre Louis Inst Epidemiol & Publ Hlth,INS, Publ Hlth Dept,Ctr Pharmacoepidemiol Cephepi CIC, Paris, France

[8] Toulouse Univ Hosp, Dermatol Dept, Toulouse, France

[9] Paul Sabatier Univ, UMR INSERM 1056, Toulouse, France

[10] Robert Debre Univ Hosp, Dermatol Dept, Reims, France

[11] Victor Dupouy Hosp, Dermatol Dept, Argenteuil, France

[12] Le Mans Hosp, Dermatol Dept, Le Mans, France

[13] Lyon Univ Hosp, Edouard Herriot Hosp, HCL, Dermatol Dept, Lyon, France

[14] Univ Hosp, La Timone Hosp, Dermatol Dept, Marseille, France

[15] Normandie Univ, Rouen Univ Hosp, Dept Dermatol, INSERM 1234, Caen, France

[16] Rennes Univ Hosp, Hop Pontchaillou, Dermatol Dept, Rennes, France

[17] Rennes 1 Univ, Inserm CIC 1414, Rennes, France

[18] Ctr Invest Clin 1430, INSERM, Creteil, France

[19] Paris Est Creteil Univ, USC ANSES, Creteil Med Sch, Res Grp Dynam,EA7380,Natl Vet Sch Alfort, Creteil, France

来源：

ACTA DERMATO-VENEREOLOGICA | 2022年 / 102卷

关键词：

psoriasis; drug survival; treatment; biologic; apremilast; MODERATE; EFFICACY; SAFETY;

D O I：

10.2340/actadv.v101.566

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Drug survival reflects treatment effectiveness and safety in real life. There is limited data on the variation of drug survival with the availability of systemic treatments with additional biological disease-modifying antirheumatic drugs (bDMARDs) or synthetic diseasemodifying antirheumatic drugs (sDMARDs). The aim of this study was to determine whether the increasing number of available systemic treatments for psoriasis affects drug survival over time. Patients were selected from the PsoBioTeq cohort, a French prospective observational cohort enrolling patients with moderate to severe psoriasis. All patients initiating a first bDMARD or sDMARD were included. The primary outcome was comparison of drug survival over time. A multivariate Cox proportional hazard ratio model was computed. A total of 1,866 patients were included; 739 females (39%), median age 47 years. In the multivariate Cox model, no association was found between the calendar year of initiation and drug survival (hazard ratio) overlapping from 0.80 (0.42-1.52) to 1.17 (0.64-2.17), p = 0.633). In conclusion, drug survival in psoriasis is not affected by the year of initiation.

引用

页数：7

共 18 条

[1]

[Anonymous], 2015, COCHRANE DB SYST REV

[2] Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry [J].

Carrascosa, J. M. ;

Vilavella, M. ;

Garcia-Doval, I. ;

Carretero, G. ;

Vanaclocha, F. ;

Dauden, E. ;

Gomez-Garcia, F. J. ;

Herrera-Ceballos, E. ;

De la Cueva Dobao, P. ;

Belinchon, I. ;

Sanchez-Carazo, J. L. ;

Alsina, M. ;

Lopez-Estebaranz, J. L. ;

Ferran, M. ;

Peral, F. ;

Torrado, R. ;

Rivera, R. ;

Jimenez-Puya, R. ;

Mendiola, M. V. ;

Ferrandiz, C. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2014, 28 (07) :907-914

[3] Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis [J].

Davila-Seijo, P. ;

Dauden, E. ;

Carretero, G. ;

Ferrandiz, C. ;

Vanaclocha, F. ;

Gomez-Garcia, F. -J. ;

Herrera-Ceballos, E. ;

De la Cueva-Dobao, P. ;

Belinchon, I. ;

Sanchez-Carazo, J. -L. ;

Alsina, M. ;

Lopez-Estebaranz, J. -L. ;

Ferran, M. ;

Torrado, R. ;

Carrascosa, J. -M. ;

Llamas, M. ;

Rivera, R. ;

Jimenez-Puya, R. ;

Garcia-Doval, I. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 (11) :1942-1950

[4] Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis [J].

Egeberg, A. ;

Ottosen, M. B. ;

Gniadecki, R. ;

Broesby-Olsen, S. ;

Dam, T. N. ;

Bryld, L. E. ;

Rasmussen, M. K. ;

Skov, L. .

BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (02) :509-519

[5] Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis [J].

Graier, T. ;

Salmhofer, W. ;

Jonak, C. ;

Weger, W. ;

Koelli, C. ;

Gruber, B. ;

Sator, P. G. ;

Prillinger, K. ;

Mlynek, A. ;

Schuetz-Bergmayr, M. ;

Richter, L. ;

Ratzinger, G. ;

Painsi, C. ;

Selhofer, S. ;

Haering, N. ;

Wippel-Slupetzky, K. ;

Skvara, H. ;

Trattner, H. ;

Tanew, A. ;

Inzinger, M. ;

Tatarski, R. ;

Bangert, C. ;

Ellersdorfer, C. ;

Lichem, R. ;

Gruber-Wackernagel, A. ;

Hofer, A. ;

Legat, F. ;

Schmiedberger, E. ;

Strohal, R. ;

Lange-Asschenfeldt, B. ;

Schmuth, M. ;

Vujic, I ;

Hoetzenecker, W. ;

Trautinger, F. ;

Saxinger, W. ;

Muellegger, R. ;

Quehenberger, F. ;

Wolf, P. .

BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (06) :1094-1105

[6] Epidemiologic study in a real-world analysis of patients with treatment for psoriasis in the French national health insurance database [J].

Grodner, C. ;

Sbidian, E. ;

Weill, A. ;

Mezzarobba, M. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (02) :411-416

[7] Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence [J].

Lin, Pei-Tzu ;

Wang, Shu-Hui ;

Chi, Ching-Chi .

SCIENTIFIC REPORTS, 2018, 8

[8] Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQ [J].

Masson Regnault, M. ;

Castaneda-Sanabria, J. ;

Tran, M. H. T. Diep ;

Beylot-Barry, M. ;

Bachelez, H. ;

Beneton, N. ;

Chosidow, O. ;

Dupuy, A. ;

Joly, P. ;

Jullien, D. ;

Mahe, E. ;

Richard, M. -A. ;

Viguier, M. ;

Tubach, F. ;

Sbidian, E. ;

Paul, C. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (02) :293-300

[9] Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1) [J].

Papp, Kim ;

Reich, Kristian ;

Leonardi, Craig L. ;

Kircik, Leon ;

Chimenti, Sergio ;

Langley, Richard G. B. ;

Hu, ChiaChi ;

Stevens, Randall M. ;

Day, Robert M. ;

Gordon, Kenneth B. ;

Korman, Neil J. ;

Griffiths, Christopher E. M. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 73 (01) :37-49

[10] Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence [J].

Parisi, Rosa ;

Symmons, Deborah P. M. ;

Griffiths, Christopher E. M. ;

Ashcroft, Darren M. .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2013, 133 (02) :377-385

← 1 2 →